Literature DB >> 31516230

Quantification of Mycobacterium tuberculosis and Mycobacterium avium complex in human immunodeficiency virus-infected individuals with and without tuberculosis.

Yashovardhan Naishadham1, Vijay Kumar Jogishetty2, Venkat Baghirath Pacha2, Sudheer B Balla2, B Hari Vinay2, Parameshwar Naishadham2.   

Abstract

CONTEXT: For a dental practitioner, HIV-TB co-infection which is a lethal aliment is an occupational hazard by the virtue of abundant aerosol formation in day to day dental practice. AIM: To assess the prevalence of TB co-infection among HIV patients. To assess the infectivity by culturing Mycobacterium Tuberculosis and Mycobacterium avium complex using Lowenstein Jensen medium and Middlebrook medium. SETTING AND
DESIGN: One hundred and forty one recently diagnosed HIV seropositive patients were selected. They were divided into two group based on their clinical symptomatology. Sputum samples, CD4 counts and brief case history were collected from these patients. SUBJECTS AND METHODS: Sputum samples were homogenized using modified Petroff 's method. The samples were cultured using Lowenstein Jensen and Middlebrook media. Cultures were interpreted after two weeks of incubation and the cultures were quantified based on their number of colonies produced on them. STATISTICAL ANALYSIS: Descriptive statistical analyses followed by Chi square test were performed to assess the prevalence and variation of TB co-infection.
RESULTS: Prevalence of TB in our sample is 25.53%. Higher CFU of MTB and MAC are obtained in patients symptomatic for TB. MB yields higher CFU than LJ.
CONCLUSION: Clinical symptoms alone cannot act as basis for suspecting TB in HIV patients. Mycobacterial cultures should be used as diagnostic aids and preferably both the mediums have to be used.

Entities:  

Keywords:  HIV; LJ; MAC; Middlebrook; Quantification; Tuberculosis

Year:  2019        PMID: 31516230      PMCID: PMC6714263          DOI: 10.4103/jomfp.JOMFP_194_18

Source DB:  PubMed          Journal:  J Oral Maxillofac Pathol        ISSN: 0973-029X


INTRODUCTION

Human immunodeficiency virus (HIV) thrives on death. During the early 1980s, numerous cases have been reported primarily from Africa with patients showing severe weakness, anorexia and vomiting in conjunction with a rare malignancy known as Kaposi's sarcoma, which showed an increase in incidence.[1] In 1983, Luc Montagnier and Robert Gallo led separate research teams successfully isolating a viral strain from such patients and named it HIV.[23] HIV, as the name indicates, leads to immunosuppression by targeting CD4 cells in the circulation.[4] A decrease in the CD4 counts to a varying degree is seen in all the patients infected with HIV.[5] As a result of this immunosuppression, various opportunistic infections arise within the patients. Globally, candidiasis is the leading opportunistic infection; however, in India, candidiasis is paralleled by tuberculosis (TB) in prevalence. TB, also known as “The White Plague,” is a communicable, granulomatous, airborne bacterial infection caused by Mycobacterium tuberculosis (MTB). TB has been known to humankind since ancient times and is responsible for most deaths caused by any disease.[6] TB spreads through droplet formation, which is intensified by aerosols encountered regularly in a dental practice. As the organism is fastidious and highly contagious, additional care is necessary for patient management. Unfortunately, the immunosuppression caused by HIV acts as an adjunct to TB, resulting in a coinfection and thereby an increase in incidence. TB classically presents as a persistent cough for more than 2 weeks. Weight loss, night sweats and fever along with cough are considered as the cardinal signs of TB. However, these clinical symptoms are subjected to an individual and geographical variation in case of an HIV-TB coinfection. The WHO has proposed clinical guidelines to counter HIV-TB pandemic. These guidelines are based on taking a detailed history of the patient. Due to inconsistency in the CD4 counts, patient's clinical presentations and histories, clinical guidelines alone cannot be considered as a safe means of diagnosis.[7] TB has been diagnosed since the early 20th century by sputum smear microscopy using Zeil–Neilson or acid-fast bacilli staining. Since the 1970s, culture of MTB using Lowenstein–Jensen medium (LJ) has been used as a gold standard for diagnosis.[8] A decade ago, with the advent of molecular diagnostic aids and complete identification of mycobacterial genome, nucleic acid amplification tests had been performed to diagnose TB with an accuracy of 90%.[9] In India, their sensitivity and specificity are overshadowed by their expensiveness and inaccessibility. This situation demands the development of new parameters for diagnosing and predicting the possibility of TB development in HIV-positive patients, which are economical, easy, rapid to perform and reliable. In the present cross-sectional study, correlation between CD4 counts of HIV-seropositive patients with culture positivity in terms of colony counts is performed to establish the predictive role of CD4 counts for TB in HIV-positive patients. Similarly, correlation between culture status and the presence of symptoms suggestive of TB is performed to assess the reliability of clinical symptoms in predicting TB in HIV-infected patients.

MATERIALS AND METHODS

The present study was conducted at Mahatma Gandhi General Hospital and Panineeya Mahavidyalaya Institute of Dental Sciences Hospital and Research Center in Hyderabad. The study was approved by the institutional ethical committee (PMVIDS/OP/0018/2014). The present study included a sample of 141 individuals who were recently diagnosed with HIV. Brief case history, CD4 counts and sputum samples were collected from patients. Patients who were receiving antiretroviral treatment (ART) or antitubercular treatment (ATT) were excluded. Any patient with a prior history of TB was also excluded from the study. The 141 individuals were divided into study and control groups based on their clinical symptomatology. Individuals with symptoms suggestive of TB such as cough, dyspnea, chest pain and hemoptysis were included under the control group and those without the symptoms were included under the study group, respectively. Sputum samples were collected following the WHO protocol in the presence of an observer. Two milliliters of the stimulated sputum sample was collected in a wide-mouthed, sterile, screw-capped bottle held slight away from the mouth. Care was taken that saliva would not mix with sputum by instructing the patient to take a deep breath and expectorate the sputum directly into the sample collection bottle without touching its walls.[10] Blood samples were preferably collected on the same day or the next. The sputum samples were homogenized following the Revised National TB Control Program guidelines using modified Petroff's method.[11] The conventional LJ medium was used for culture along with Middlebrook 7H11 (MB) medium which has greater sensitivity for Mycobacterium avium complex (MAC) in comparison to LJ medium. The processed sputum sample was inoculated on one slant of LJ medium and MB medium each. The media were incubated at 37°C for 2 weeks. At the end of 2 weeks of incubation, positive cultures were identified and speciation was performed based on colony morphology. MTB yielded rough, buff-colored colonies [Figures 1 and 2], whereas MAC yielded smooth, waxy, cream-colored colonies [Figure 3]. MAC also yield red-colored pigmented colonies [Figure 4]. Number of discrete colonies was counted, and as the dilution factor along with the volume of sample inoculated was known, number of colony forming units (CFU) was calculated using the formula:
Figure 1

Mycobacterium tuberculosis colonies on Lowenstein–Jensen medium

Figure 2

Mycobacterium tuberculosis colonies on Middlebrook medium

Figure 3

Mycobacterium avium complex showing smooth, waxy nonpigmented colonies on Middlebrook medium

Figure 4

Mycobacterium avium complex showing confluent growth and pigmented colonies on Middlebrook medium

Mycobacterium tuberculosis colonies on Lowenstein–Jensen medium Mycobacterium tuberculosis colonies on Middlebrook medium Mycobacterium avium complex showing smooth, waxy nonpigmented colonies on Middlebrook medium Mycobacterium avium complex showing confluent growth and pigmented colonies on Middlebrook medium Chi-square test was performed to correlate the variation of CD4 counts with culture positivity using LJ and MB media. Variation of culture positivity with clinical symptomatology was also assessed. Statistical significance was set as P < 0.05.

RESULTS

Our sample includes 141 individuals recently diagnosed as HIV seropositive. Our sample distribution is depicted in Tables 1 and 2. Among the 141 subjects, 79 belonged to the control group and 62 belonged to the study group. Similarly, 55 were males and 86 were females. Within the control group, 34 were males and 45 were females, and within the study group, 21 were males and 41 were females.
Table 1

Age distribution among the control and study groups

Control group (%)Study group (%)Total (%)
18-25 years8 (10.13)10 (16.13)18 (12.77)
26-34 years36 (45.57)22 (35.48)58 (41.13)
35-44 years24 (30.38)16 (25.81)40 (28.37)
45-65 years11 (13.92)14 (22.58)25 (17.73)
Total79 (100.00)62 (100.00)141 (100.00)
Mean age34.67±9.1635.56±10.6735.06±9.82
Table 2

Sex distribution within control and study groups

Control group (%)Study group (%)Total (%)
Male34 (43.04)21 (33.87)55 (39.01)
Female45 (56.96)41 (66.13)86 (60.99)
Total79 (100.00)62 (100.00)141 (100.00)
Age distribution among the control and study groups Sex distribution within control and study groups Our sample was divided into four groups based on CD4 counts, namely, <200, 201–349, 350–500 and >501. A P = 0.508 was obtained which was not statistically significant. CD4 count distribution in our sample is shown in Table 3.
Table 3

Distribution of CD4 counts in the sample

Control group (%)Study group (%)Total (%)
<20029 (36.70)20 (32.26)49 (34.77)
201-34914 (17.73)7 (11.29)21 (14.89)
350–50014 (17.73)16 (25.80)30 (21.26)
≥50122 (27.84)19 (30.65)41 (29.08)
Total79 (100.00)62 (100.00)141 (100.00)

P=0.508; not significant; no significant variation was found among CD4 counts with respect to clinical symptoms

Distribution of CD4 counts in the sample P=0.508; not significant; no significant variation was found among CD4 counts with respect to clinical symptoms Comparative evaluation of culture positivity with respect to clinical symptomatology is presented in Table 4. Of the total 141 individuals, 36 showed culture positivity and 105 showed culture negativity. Within the control group, 21 individuals showed culture positivity and 58 showed culture negativity, whereas, among individuals of the study group, 15 showed culture positivity and 47 showed culture negativity. A P = 0.7473 was obtained which was not statistically significant.
Table 4

Culture status of the sample using both the media

Control group (%)Study group (%)Total (%)
Positive21 (26.58)15 (24.19)36 (25.53)
Negative58 (73.42)47 (75.81)105 (74.47)
Total79 (100.00)62 (100.00)141 (100.00)

P=0.7473; not significant; significant variation between culture positivity and clinical symptoms was not found

Culture status of the sample using both the media P=0.7473; not significant; significant variation between culture positivity and clinical symptoms was not found Culture positivity for MTB using LJ medium and its variation with respect to CD4 counts and clinical symptomatology is described in Table 5. A P = 0.017 was obtained which was statistically significant. In the study group, 14 were positive of which five had CD4 counts <200 cells/mm3, three had CD4 counts ranging between 350 and 500 cells/mm3 and six had >501 cells/mm3. In the control group, 15 were positive of which eight had CD4 counts <200 cells/mm3.
Table 5

Culture positivity for Mycobacterium tuberculosis using Lowenstein-Jensen medium with respect to their CD4 counts

Control group (%)Study group (%)Total (%)
<2008 (53.33)5 (35.71)13 (44.83)
201-3495 (33.33)0 (0.00)5 (17.24)
350-5001 (6.67)3 (21.43)4 (13.79)
≥5011 (6.67)6 (42.86)7 (24.14)
Total15 (100.00)14 (100.00)29 (100.00)

P=0.017; significant; culture positivity using Lowenstein Jensen medium showed significant variation with CD4 counts

Culture positivity for Mycobacterium tuberculosis using Lowenstein-Jensen medium with respect to their CD4 counts P=0.017; significant; culture positivity using Lowenstein Jensen medium showed significant variation with CD4 counts Among the individuals positive for MTB using LJ medium, those with CD4 counts below 200 cells/mm3 had a mean of 151.38 CFU. The mean CFU obtained from the control group and study group was 94 ± 166.19 and 81 ± 154.42, respectively. A P = 0.269 was obtained which was not statistically significant. Variation among the mean CFU of MTB with respect to CD4 counts and clinical symptomatology using LJ medium is depicted in Table 6.
Table 6

Mean colony forming units of Mycobacterium tuberculosis using Lowenstein-Jensen medium in control and study groups with respect to their CD4 counts

Control groupMean CFUStudy groupMean CFUTotalMean CFU
<2008151.505151.2013151.38
201-349533.6000533.60
350-500112.00332.00427.00
≥501118.00647.00742.85
Mean CFU94.00±166.1981±154.4287.724±157.87

P=0.269; not significant. Variation of colony forming units using Lowenstein Jensen medium with respect to CD4 counts was not significant CFU: Colony forming units

Mean colony forming units of Mycobacterium tuberculosis using Lowenstein-Jensen medium in control and study groups with respect to their CD4 counts P=0.269; not significant. Variation of colony forming units using Lowenstein Jensen medium with respect to CD4 counts was not significant CFU: Colony forming units Culture positivity for MAC using MB medium and its variation with respect to CD4 counts and clinical symptomatology is shown in Table 7. In the control group, four were positive of which one had CD4 counts ranging between 201 and 349 cells/mm3 and three had CD4 count >501 cells/mm3. In the study group, one was positive with CD4 counts ranging between 350 and 500 cells/mm3. A P = 0.082 was obtained which was not statistically significant.
Table 7

Culture positivity for Mycobacterium avium complex using Middlebrook 7H11 medium with respect to their CD4 counts

CD4 countsControl group (%)Study group (%)Total (%)
<2000 (0.00)0 (0.00)0 (0.00)
201-3491 (25.00)0 (0.00)1 (20.00)
350-5000 (0.00)1 (100.00)1 (20.00)
≥5013 (75.00)0 (0.00)3 (60.00)
Total4 (100.00)1 (100.00)5 (100.00)

P=0.082; not significant; culture positivity using Middlebrook medium showed no significant variation with CD4 counts

Culture positivity for Mycobacterium avium complex using Middlebrook 7H11 medium with respect to their CD4 counts P=0.082; not significant; culture positivity using Middlebrook medium showed no significant variation with CD4 counts In the control group, the mean CFU of MAC was 541.50 ± 338.18. Similarly, the study group yielded a CFU of 744.00. Variation among the mean CFU of MAC with respect to CD4 counts and clinical symptomatology using MB medium is presented in Table 8.
Table 8

Mean colony forming units for Mycobacterium avium complex using Middlebrook 7H11 medium with respect to their CD4 counts

CD4 countsControl groupMean CFUStudy groupMean CFUTotalMean CFU
<20000.0000.0000.00
201-349136.0000.00136.00
350-50000.001744.001744.00
≥5013710.0000.003710.00
Mean CFU541.50±338.18744.00582.00±306.55

P=0.746; not significant. Variation of colony forming units using Middlebrook medium with respect to CD4 counts was not significant CFU: Colony forming units

Mean colony forming units for Mycobacterium avium complex using Middlebrook 7H11 medium with respect to their CD4 counts P=0.746; not significant. Variation of colony forming units using Middlebrook medium with respect to CD4 counts was not significant CFU: Colony forming units

DISCUSSION

HIV is an incapacitating disease and causes numerous opportunistic infections, due to its immunosuppression, which makes it lethal to humanity. In 2014, the WHO reported that there were 35 million people all over the world living with HIV, and among them, 1.1 million people were diagnosed with TB. Along with MTB, various strains of nontuberculous mycobacteria (NTM) were isolated from HIV-TB-coinfected patients in recent years.[1213] In India, TB is the second most common opportunistic infection in HIV-infected patients following candidiasis.[10] In 2014, the WHO proposed a tetrad of clinical symptoms for diagnosing HIV-TB coinfection which includes cough, fever, night sweats and weight loss in a decreasing order of presentation.[13] According to Swaminathan et al., in the Indian population, there was variation in the clinical presentation of HIV-TB coinfection, with cough and weight loss being the most prevalent symptoms, whereas fever and night sweat being observed occasionally.[14] CD4 counts have been used as a reliable indicator for immunosuppression in HIV patients, and hence, CD4 counts have been compared with the culture status in HIV-TB coinfection to assess the diagnostic reliability of this correlation. In 1997, Jones et al. stated that there is a reduction in the CD4 count with increasing culture positivity, but it is not statistically significant.[15] In 2015, Mishra and Rukadikar published similar results in the Indian population using LJ medium.[16] In the present study, we have selected individuals who were not on ART or ATT because, in a cross-sectional study conducted by Wanchu et al., they reported that both ATT and ART influence the CD4 counts of patients.[17] We have used MB medium in addition to LJ medium because, according to Thoen et al., it was not only more sensitive in detecting MTB than LJ but also useful in isolating colonies of MAC. Furthermore, it helps in differentiating rapid-growing mycobacteria from slow-growing mycobacteria.[18] The prevalence of TB in our study based on clinical symptoms is 56.04%, which is higher than that reported by Aggarwal et al. and Swaminathan et al., who reported a prevalence of 31.25% and 43.58%, respectively. The difference in the prevalence can be attributed to the use of a smaller sample than our study.[1419] The prevalence of TB in the present study based on the use of a diagnostic test is 25.53%, which is higher than that reported by Sameer Singhal et al., who reported a prevalence of 11.2%. The decreased prevalence of their study could be attributed to the use of sputum smear microscopy for the detection of TB, which is a less sensitive method compared to cultures.[2021] Mishra and Rukadikar reported a prevalence of 23.48%, which is very similar to our result. The similarity can be attributed to the use of LJ medium for culturing sputum sample.[16] Conversely, Swaminathan et al. reported a higher prevalence of 31.25%, and this could be attributed to the use of Mantoux test for diagnosis, which gives higher false-positive results when compared to cultures.[14] In the present study, we observed that of 36 (25.53%) individuals who were positive for TB, only 33 (23.41%) were reported positive using LJ medium. Our results are similar to those of Naveen and Peerapur, who reported that of 120 individuals who were positive for TB in their study, only 65 were positive with LJ medium.[21] This difference in positivity could be due to the interpretation of the cultures at the end of the 2nd week because the peak positivity of LJ medium is in the 4th week. The cultures on LJ medium are interpreted by the end of the 2nd week as there is an increased chance of contamination on further incubation. By this observation, we understand that the use of LJ medium alone could lead to misdiagnosing few patients as TB negative. In the present study, we observed that of 36 (25.53%) individuals who were positive for TB, only 25 (17.73%) were reported positive using MB medium. From this observation, we could infer that MB is less sensitive for TB when compared to LJ medium. These results are in agreement to those of Naveen et al., who stated that MB medium shows only 69% sensitive for TB in comparison to LJ medium.[22] The decreased sensitivity could be due to the absence of carbon dioxide production from the medium, which is need for mycobacterial growth. Among the 36 individuals who were culture positive in our study, 14 (38.89%) had CD4 counts <200 cells/mm3 while 10 (27.77%) had CD4 counts above 500 cells/mm3. This variation yielded a P = 0.837 which is not significant, indicating that decrease in CD4 count does not result in an increase in culture positivity among the individuals. Our results are in conflict with Jones et al., who reported TB positivity with CD4 counts below 200 cells/mm3 and above 500 cells/mm3 while showing a significant variation.[15] This difference could be due to the use of LJ medium alone in their study. Few cultures from severe immunocompromised individuals showed fungal growth within 2 days of inoculation on LJ medium. After 2 weeks of inoculation, rough, buff-colored colonies developed amid the fungal growth. They were reported as MTB positive. This interpretation is in accordance with Mwaura et al., who reported that Candida (19.18%) is the most common fungal organism isolated from sputum samples of TB patients, and appearance of fungal growth on LJ medium should not be interpreted as contamination if MTB colonies are seen within 2 weeks of inoculation.[23] In the previous studies, the tuberculous colonies were graded according to the number of discrete colonies that are obtained on the slopes; however, in the present study, we have expressed the colonies in the form of CFU, as a known volume of sputum with a standardized dilution was used to inoculate the media. Our results show that using LJ medium subjects of the control group (94 ± 166.19) yielded higher colony counts for MTB in comparison to the study group (81 ± 154.42). A P = 0.269 was achieved indicating a nonsignificant variation of mean CFU among the control and study groups. Our search through the literature shows few studies that expressed MTB and MAC in the form of CFU; however, we cannot compare our results with them as the former studies quantified the cultures as CFU only in secondary cultures.

CONCLUSION

If an individual is diagnosed with HIV-TB coinfection, it is safe to assume that the severity of the disease increases with the appearance of clinical symptoms and the degree of immunosuppression. As TB shares clinical symptoms with numerous opportunistic infections, clinical symptoms alone should not be used as the basis of suspicion. NTM such as MAC show similar clinical presentation to MTB and they do not respond to ATT; hence, if a subject is nonresponsive for ATT, it indicates not only multidrug-resistant MTB but also MAC. Asymptomatic patients and those who are not suspected of TB along with those who are not qualified for ATT are also showing culture positivity, indicating a potential threat. Accurate diagnosis helps the patient to receive proper treatment before the disease advances to a refractory stage, and it also helps the dental practitioners prevent cross-contamination. Clinical symptoms can be used as basis for suspecting MAC alone in HIV patients, and MB medium has to be used if MAC is suspected. The mean CFU reflects the severity of disease better than grading the cultures based on number of colonies. Our study establishes that asymptomatic patients with CD4 counts above 350 cells/mm3 who do not qualify for chemotherapy are culture positive for MTB, indicating a need in increasing the range for CD4 counts eligible for chemotherapy. It emphasizes on the need for diagnosing TB through LJ and MB cultures, which has taken a back seat in comparison to sputum smear microscopy which is less sensitive and National Assessment and Accreditation Council tests which are less economic and accessible to the general population.

Financial support and sponsorship

Nil.

Conflicts of interest

There are no conflicts of interest.
  12 in total

Review 1.  Immune suppression and considerations for dental care.

Authors:  Ernesta Parisi; Michael Glick
Journal:  Dent Clin North Am       Date:  2003-10

2.  Mycobacterium tuberculosis complex DNA from an extinct bison dated 17,000 years before the present.

Authors:  B M Rothschild; L D Martin; G Lev; H Bercovier; G K Bar-Gal; C Greenblatt; H Donoghue; M Spigelman; D Brittain
Journal:  Clin Infect Dis       Date:  2001-07-05       Impact factor: 9.079

3.  CD4 cell count recovery in HIV/TB co-infected patients versus TB uninfected HIV patients.

Authors:  A Wanchu; V S Kuttiatt; A Sharma; S Singh; S Varma
Journal:  Indian J Pathol Microbiol       Date:  2010 Oct-Dec       Impact factor: 0.740

4.  Correlation of sputum smear status with CD4 count in cases of pulmonary tuberculosis and HIV co-infected patients--a hospital based study in a rural area of Central India.

Authors:  Sameer Singhal; S N Mahajan; S K Diwan; Abhay Gaidhane; Z S Quazi
Journal:  Indian J Tuberc       Date:  2011-07

Review 5.  Origins of HIV and the AIDS pandemic.

Authors:  Paul M Sharp; Beatrice H Hahn
Journal:  Cold Spring Harb Perspect Med       Date:  2011-09       Impact factor: 6.915

Review 6.  The origins of the human immunodeficiency viruses: an update.

Authors:  A J Smith; D M Walker
Journal:  J Oral Pathol Med       Date:  1992-04       Impact factor: 4.253

Review 7.  Microscopy as a diagnostic tool in pulmonary tuberculosis.

Authors:  Ritu Singhal; Vithal Prasad Myneedu
Journal:  Int J Mycobacteriol       Date:  2015-02-02

8.  Comparison of the Lowenstein-Jensen Medium, the Middlebrook 7H10 Medium and MB/BacT for the Isolation of Mycobacterium Tuberculosis (MTB) from Clinical Specimens.

Authors:  G Naveen; Basavaraj V Peerapur
Journal:  J Clin Diagn Res       Date:  2012-12-15

Review 9.  Diagnosis & treatment of tuberculosis in HIV co-infected patients.

Authors:  C Padmapriyadarsini; G Narendran; Soumya Swaminathan
Journal:  Indian J Med Res       Date:  2011-12       Impact factor: 2.375

Review 10.  Cytopathic mechanisms of HIV-1.

Authors:  Joshua M Costin
Journal:  Virol J       Date:  2007-10-18       Impact factor: 4.099

View more
  1 in total

1.  Prevalence of oral lesions in tuberculosis: A cross sectional study.

Authors:  Purnendu Rout; Varsha Modipalle; Shruthi S Hedge; Nirav Patel; Sravani Uppala; Prajwal K Shetty
Journal:  J Family Med Prim Care       Date:  2019-12-10
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.